Antiviral Drugs - Algeria

Algeria

In Algeria, the revenue in the Antiviral Drugs market is forecasted to reach US$40.23m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 0.86%, which will lead to a market volume of US$41.99m by 2029.
When compared globally, United States is projected to generate the highest revenue in the market, amounting to US$30,640.00m in 2024.
Algeria's demand for antiviral drugs has surged in recent years due to the country's high prevalence of infectious diseases.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Algeria has been experiencing steady growth in recent years.

Customer preferences: Algeria has a high prevalence of infectious diseases, including hepatitis, HIV/AIDS, and tuberculosis. As a result, there is a high demand for antiviral drugs in the country. Additionally, the Algerian government has been investing heavily in healthcare infrastructure, which has led to an increase in access to healthcare services for the population.

Trends in the market: The Algerian antiviral drugs market is dominated by generic drugs, which are more affordable than branded drugs. The market is also seeing an increase in the use of combination therapies, which are more effective in treating certain viral infections. Furthermore, there has been a shift towards the development of new antiviral drugs that target specific viruses, rather than broad-spectrum drugs.

Local special circumstances: Algeria has a large population of young people, who are at a higher risk of contracting infectious diseases. Additionally, the country has a large rural population, which can make it difficult to provide healthcare services to everyone. The Algerian government has been working to address these issues by investing in healthcare infrastructure and increasing access to healthcare services.

Underlying macroeconomic factors: Algeria is a resource-rich country, with a large oil and gas industry. However, the country has been facing economic challenges in recent years, due to a decline in oil prices. This has led to a decrease in government spending, which could impact the healthcare sector in the long term. Additionally, Algeria has a complex regulatory environment, which can make it difficult for foreign companies to enter the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.